Patents by Inventor Jon Aster

Jon Aster has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods determining and treating cellular resistance to ADP-rtbosylating toxin
    Patent number: 11674950
    Abstract: The present invention is based in part on the identification of DPH1 and other members of the diphthamide synthesis pathway as biomarkers of resistance to an ADP-ribosylating toxin in a cell, and methods for identification, assessment, and treatment of a condition that is resistant to an ADP-ribosylating toxin.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: June 13, 2023
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Andrew Lane, Jon Aster
  • TARGETING GALECTIN-9 AS A THERAPEUTIC STRATEGY FOR T-CELL EXHAUSTION IN T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
    Publication number: 20220242955
    Abstract: The present invention relates to compositions and methods for treating early T-cell precursor acute lymphoblastic leukemia (ETP T-ALL).
    Type: Application
    Filed: July 10, 2020
    Publication date: August 4, 2022
    Applicants: DANA-FARBER CANCER INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Birgit Knoechel, Jens G. Lohr, Praveen Anand, Amy Guillaumet-Adkins, Jon Aster
  • METHODS DETERMINING AND TREATING CELLULAR RESISTANCE TO ADP-RIBOSYLATING TOXIN
    Publication number: 20210325368
    Abstract: The present invention is based in part on the identification of DPH1 and other members of the diphthamide synthesis pathway as biomarkers of resistance to an ADP-ribosylating toxin in a cell, and methods for identification, assessment, and treatment of a condition that is resistant to an ADP-ribosylating toxin.
    Type: Application
    Filed: October 30, 2018
    Publication date: October 21, 2021
    Inventors: Andrew Lane, Jon Aster
  • COMPOSITIONS AND METHODS FOR TREATING NEOPLASIAS
    Publication number: 20190185559
    Abstract: The invention provides therapeutic combinations comprising an agent that inhibits Notch signaling and an agent that inhibits B cell receptor signaling, and methods of using such agents to inhibit the survival or proliferation of a neoplastic cell.
    Type: Application
    Filed: September 1, 2017
    Publication date: June 20, 2019
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., THE GENERAL HOSPITAL CORPORATION, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: RYAN J.H. RUSSELL, BRADLEY E. BERNSTEIN, JON ASTER, WARREN S. PEAR
  • Treatment of cancers characterized by chromosomal rearrangement of the gene
    Patent number: 8623853
    Abstract: The present invention is directed, inter alia, to methods of treating NUT midline carcinoma (NMC) by administering compounds that promote increased histone acetylation. The invention also includes assay methods for determining the responsiveness of NMC to specific histone deacetylases and other compounds.
    Type: Grant
    Filed: July 21, 2009
    Date of Patent: January 7, 2014
    Assignees: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Christopher French, Jon Aster, Matthias Hofer, James Bradner
  • GENERATION AND CHARACTERIZATION OF ANTI-NOTCH ANTIBODIES FOR THERAPEUTIC AND DIAGNOSTIC USE
    Publication number: 20110286916
    Abstract: The present invention relates to mammalian antibodies, preferably fully human monoclonal antibodies and antigen-binding portions thereof that specifically bind to a cell surface receptor, wherein the receptor protein is a Notch1 receptor protein. Some of the disclosed antibodies bind Notch1 to the exclusion of other members of the Notch receptor family, while other antibodies bind Notch 1 and Notch3. Nucleic acid molecules encoding the Notch antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of Notch1 or Notch3 including aberrant activation of each of these receptors.
    Type: Application
    Filed: November 16, 2009
    Publication date: November 24, 2011
    Inventors: Jose Miguel Aste-Amezaga, Ningyan Zhang, Fubao Wang, Andrew Bett, Anna Demartis, Maurizio Nuzzo, Paolo Monaci, Stephen Blacklow, Jon Aster
  • Treatment of Cancers Characterized by Chromosomal Rearrangement of the NUT Gene
    Publication number: 20110213012
    Abstract: The present invention is directed, inter alia, to methods of treating NUT midline carcinoma (NMC) by administering compounds that promote increased histone acetylation. The invention also includes assay methods for determining the responsiveness of NMC to specific histone deacetylases and other compounds.
    Type: Application
    Filed: July 21, 2009
    Publication date: September 1, 2011
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE
    Inventors: Christopher French, Jon Aster, Matthias Hofer, James Bradner
  • NOTCH mutations leading to increased receptor signaling
    Publication number: 20070077245
    Abstract: The present invention is based upon the identification of regions within the NOTCH-1 receptor that, when mutated, lead to increased receptor signaling. The mutations are associated with uncontrolled cellular growth and this growth may be arrested using agents that interfere with NOTCH-1 activity, such as inhibitors of gamma-secretase. Assays for the NOTCH-1 mutations may be used diagnostically or as part of a treatment regimen for cancer patients.
    Type: Application
    Filed: August 2, 2005
    Publication date: April 5, 2007
    Applicants: The Brigham and Women's Hospital, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Jon Aster, Stephen Blacklow, A. Look, Adolfo Ferrando, Andrew Weng